(October 22, 2025, Shanghai, China) Recently, Fosun Pharma (SSE: 600196；HKEX: 02196) and Helsinn Group (“Helsinn”) signed a technology transfer agreement in Shanghai to enable local manufacturing of Fosnetupitant and Palonosetron Concentrated Solution for Injection.

The signing ceremony was attended by Mr. Chen Yuqing, Chairman of Fosun Pharma, Dr. Melanie Rolli, CEO ofHelsinn, and senior management representatives from both sides. The agreement was signed by Ms. Li Jing, Co-President, the Chief Executive Officer of Established Medicines Manufacturing and Supply Division, and Mr. Andrea Pontiggia, Head of International Commercial Business at Helsinn. This milestone marks the transition of the partnership from commercial collaboration to deeper industrial integration, further accelerating the localization of this globally leading antiemetic in China.

"We are delighted to further strengthen our collaboration with Helsinn expanding from commercialization to local manufacturing. This represents not only the culmination of our long-standing trust and partnership, but also a key milestone in Fosun Pharma’s efforts to accelerate the localization of innovative medicines and enhance supply chain resilience and efficiency.” Mr. Chen Yuqing, Chairman of Fosun Pharma, said, “Leveraging Fosun Pharma’s robust industrial platform and extensive market presence in China, the local production of Fosnetupitant and Palonosetron Concentrated Solution for Injection is expected to further improve drug accessibility, offering Chinese patients more efficient, convenient, and high-quality treatment options, and contributing to the ‘Healthy China’ initiative."

“We are truly excited about the strategic collaboration with Fosun Pharma for the localized manufacturing of Fosnetupitant and Palonosetron Concentrated Solution for Injection.” Dr. Melanie Rolli, CEO of Helsinn said, “We have maintained an excellent partnership over the years and look forward to exploring further possibilities of working together in the future, ultimately benefiting more Chinese patients and addressing unmet clinical needs.”

In October 2021, Fosun Pharma entered into an agreement with Helsinn, obtaining exclusive rights for the licensing, distribution, and promotion of several related oncology supportive care products, including Akynzeo^® oral capsule, in mainland China, Hong Kong, and Macao. Among them, the Akynzeo^® oral capsule has been approved in China in 2019 and has been included in the National Reimbursement Drug List (NRDL) since 2023, providing an important clinical solution for cancer patients to prevent chemotherapy-induced nausea and vomiting (CINV). This also laid a solid foundation for the current expansion into localized production of the concentrated solution for injection. Netupitant and palonosetron hydrochloride capsule is currently the only combination antiemetic drug exhibiting synergistic effects^{1 2}, with a half-life of up to 96 hours for netupitant and 40 hours for palonosetron^{3 4}, The no rescue medication rate in delayed CINV phase reaches as high as 97.6%⁵.

Fosnetupitant and Palonosetron Concentrated Solution for Injection is the injection formulation of Akynzeo^® oral capsule. Currently, the marketing application for the Fosnetupitant and Palonosetron Concentrated Solution for Injection product has been accepted for review by the National Medical Products Administration (NMPA). The signing of this localized production technology transfer agreement will efficiently align with the approval process for the original-imported concentrated solution for injection. Together with the already marketed oral capsule, it will offering patients more flexible choices.

From the patient perspective, localized production will significantly shorten the supply chain cycle, it is expected to further enhance the accessibility of high-quality innovative medicines, benefiting more cancer patients. From an industrial perspective, this localized manufacturing agreement will facilitate alignment of injectable formulation and API manufacturing technologies with international standards, setting a benchmark for industrial upgrading in oncology supportive care.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; SSE: 600196, HKEX: 02196) is a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce.

Over the past 30 years since its establishment, Fosun Pharma has maintained deep roots in China while strategically expanding its global presence. The company has been actively implementing its “4IN” strategy - Innovation, Internationalization, Intelligentization, and Integration, with core business operations now spanning major overseas markets including the United States, Europe, Africa, India, and Southeast Asia. At present, Fosun Pharma has established an open and globally integrated pharmaceutical R&D ecosystem, focusing on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery. This multidimensional approach accelerates the translation of innovative therapies into clinical practice, systematically addressing critical unmet medical needs worldwide.

Looking ahead, Fosun Pharma remains anchored in its core values of “Care for life, Continuous innovation, Pursuit of excellence, and Sustainable partnership”. By advancing its global innovation engine and operational excellence, the company strives to be a global leader to integrate pharmaceutical and healthcare innovations, creating better health for families worldwide.

About Helsinn Group

Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic diseases, with a focus on supportive care, oncology and dermato-oncology. Headquartered in Lugano, Switzerland, Helsinn has direct commercial operations in the U.S., manufacturing operations in Ireland, offices in China and a network of trusted partners enabling a commercial presence in 90 countries.

Established in 1976, Helsinn is a fourth-generation family-owned company with broad pharmaceutical and technical expertise. For nearly half a century, Helsinn has been operating with integrity, passion, and quality. The company continuously strives for innovation for its patients and embraces sustainable growth as a core element of its strategic vision.

To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and X.

 ______________________________________________________

1Stathis M et al. Eur J Pharmacol.2012 Aug 15;689(1-3):25-30

2Thomas AG et al.Exp Brain Res. 2014 Aug;232(8):2637-44

3Lorusso V et al. Future Oncol. 2015 (11):565-577

4Rojas C, et al. Eur J Pharmacol.2014 Jan 5:722:26-37

5Zhang L. et al.Ann Oncol. 2018;29(2):452-458